What is Gt Biopharma Inc's earnings per share (EPS)?

Gt Biopharma Inc (GTBP) reported diluted earnings per share of $-6.68 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Gt Biopharma Inc Financials

GTBP

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows Gt Biopharma Inc (GTBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GTBP FY2025 2026-05-15

GT Biopharma remains a cash-funded development business whose operating model depends on recapitalization rather than revenue-funded growth.

FY2025’s balance-sheet repair was financed, not earned: financing cash flow of $15.8M more than offset operating cash burn of $12.9M, moving the company from FY2024’s negative equity and sub-1.0x liquidity to $6.8M of cash and a 3.5x current ratio. That means the business currently functions through periodic capital raises, with operations still consuming cash instead of replenishing it.

Reported losses narrowed from FY2021 to FY2025, but with no revenue base in the data that looks more like expense reduction than true operating leverage, because there is still no sales base to absorb overhead. SG&A fell from $47.9M to $9.0M, while R&D also stepped down materially over the period.

Liquidity looks stronger than a year earlier, but funding dependence has not gone away because pressure comes from replenishing cash, not from a heavy creditor load. At the FY2025 operating cash burn rate of $12.9M, the year-end cash balance of $6.8M covered only about half a year.

Financial Health Signals

Financial Profile 27/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Gt Biopharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Gt Biopharma Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.50, Gt Biopharma Inc holds $3.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 68/100.

Returns

Gt Biopharma Inc generates a -490.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

2/9

Gt Biopharma Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.46x

For every $1 of reported earnings, Gt Biopharma Inc generates $0.46 in operating cash flow (-$12.9M OCF vs -$28.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-97.8x

Gt Biopharma Inc earns $-97.8 in operating income for every $1 of interest expense (-$12.4M vs $127K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$28.4M

YoY-115.4%

Gt Biopharma Inc reported -$28.4M in net income in fiscal year 2025. This represents a decrease of 115.4% from the prior year.

EPS (Diluted)

$-6.68

Gt Biopharma Inc earned $-6.68 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$6.8M

YoY+72.4%

5Y CAGR+5.2%

10Y CAGR+64.5%

Gt Biopharma Inc held $6.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

26M

Gt Biopharma Inc had 26M shares outstanding in fiscal year 2025. This represents an increase of 1042.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-490.0%

Gt Biopharma Inc's ROE was -490.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$3.5M

YoY-40.1%

5Y CAGR+48.2%

Gt Biopharma Inc invested $3.5M in research and development in fiscal year 2025. This represents a decrease of 40.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GTBP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.5M-40.1%	$5.8M-10.3%	$6.5M-26.6%	$8.8M-8.1%	$9.6M+1877.5%	$485K
SG&A Expenses	$8.9M+4.5%	$8.6M+20.5%	$7.1M-42.9%	$12.4M-74.0%	$47.9M+663.2%	$6.3M
Operating Income	-$12.4M+13.5%	-$14.4M-5.8%	-$13.6M+36.1%	-$21.3M+63.0%	-$57.5M-750.3%	-$6.8M
Interest Expense	$127K	N/A	$213K+2562.5%	$8K-98.9%	$718K+123.9%	-$3.0M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$28.4M-115.4%	-$13.2M-73.3%	-$7.6M+63.6%	-$20.9M+64.0%	-$58.0M-105.0%	-$28.3M
EPS (Diluted)	$-6.68	$-6.94-23.0%	$-5.64+71.3%	$-19.66	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$413K	N/A	$634K+74.7%	$363K-67.0%	$1.1M	N/A	$1.3M-26.7%	$1.8M
SG&A Expenses	$2.4M	N/A	$2.7M+139.0%	$1.1M+38.1%	$833K	N/A	$2.3M+8.2%	$2.1M
Operating Income	-$2.8M	N/A	-$3.4M-123.5%	-$1.5M+21.7%	-$1.9M	N/A	-$3.6M+7.7%	-$3.9M
Interest Expense	$63K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.8M	N/A	$8.3M+127.5%	-$30.2M-3787.8%	-$776K	N/A	-$3.4M+8.1%	-$3.7M
EPS (Diluted)	$-0.11	N/A	$1.04+109.5%	$-10.92-3209.1%	$-0.33	N/A	$-1.53+29.5%	$-2.17

GTBP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.1M+91.5%	$4.2M-70.0%	$14.1M-15.7%	$16.7M-48.0%	$32.2M+468.3%	$5.7M
Current Assets	$8.1M+91.5%	$4.2M-69.9%	$14.1M-15.1%	$16.6M-48.5%	$32.2M+468.3%	$5.7M
Cash & Equivalents	$6.8M+72.4%	$4.0M+266.2%	$1.1M-81.0%	$5.7M-36.8%	$9.0M+69.3%	$5.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M-60.7%	$5.9M-11.0%	$6.6M+32.6%	$5.0M-51.2%	$10.3M-70.8%	$35.1M
Current Liabilities	$2.3M-60.7%	$5.9M-11.0%	$6.6M+34.3%	$4.9M-51.9%	$10.3M-70.8%	$35.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.8M+446.5%	-$1.7M-122.3%	$7.5M-36.3%	$11.7M-46.4%	$21.9M+174.4%	-$29.4M
Retained Earnings	-$723.9M-4.1%	-$695.2M-1.9%	-$682.1M-1.1%	-$674.5M-3.2%	-$653.6M-9.7%	-$595.8M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	N/A	$8.1M+87.6%	$4.3M-39.3%	$7.1M	N/A	$4.2M-37.4%	$6.8M-27.1%	$9.3M
Current Assets	$10.0M+23.3%	$8.1M+87.6%	$4.3M-39.3%	$7.1M+168.0%	$2.7M-37.2%	$4.2M-37.4%	$6.8M-27.1%	$9.3M
Cash & Equivalents	$8.9M+31.0%	$6.8M+169.4%	$2.5M-51.6%	$5.2M+121.1%	$2.4M-40.1%	$4.0M-38.4%	$6.4M-30.6%	$9.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$2.3M+75.5%	$1.3M-96.0%	$33.0M	N/A	$5.9M+26.6%	$4.7M+24.0%	$3.8M
Current Liabilities	$2.4M+4.2%	$2.3M+75.5%	$1.3M-95.7%	$31.0M+753.3%	$3.6M-38.4%	$5.9M+26.6%	$4.7M+24.0%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.6M+31.0%	$5.8M+92.9%	$3.0M+111.6%	-$25.9M-2540.3%	-$980K+41.3%	-$1.7M-179.6%	$2.1M-61.9%	$5.5M
Retained Earnings	-$726.8M-0.4%	-$723.9M-0.8%	-$718.1M+1.1%	-$726.3M-4.3%	-$696.0M-0.1%	-$695.2M-0.5%	-$691.5M-0.5%	-$688.0M

GTBP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$12.9M-0.1%	-$12.9M-45.8%	-$8.9M+41.8%	-$15.2M+2.5%	-$15.6M-114.9%	-$7.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$12.9M+741.8%	-$2.0M-116.5%	$12.1M+152.7%	-$23.0M	$0
Financing Cash Flow	$15.8M+430.1%	$3.0M-52.5%	$6.3M+2898.2%	-$224K-100.5%	$42.3M+237.7%	$12.5M
Dividends Paid	$229K	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.5M+38.6%	-$4.0M-9.4%	-$3.7M-22.0%	-$3.0M-36.9%	-$2.2M+10.8%	-$2.5M+9.8%	-$2.7M+22.6%	-$3.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$1K+200.0%	-$1K-100.0%	$7.9M
Financing Cash Flow	$4.6M-44.9%	$8.3M+750.1%	$977K-83.4%	$5.9M+854.1%	$616K	$0	$0	N/A
Dividends Paid	N/A	$144K	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GTBP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-490.0%	N/A	-101.6%+76.4pp	-178.0%+86.8pp	-264.8%	N/A
Return on Assets	-349.8%-38.8pp	-311.0%-257.2pp	-53.8%+70.9pp	-124.8%+55.6pp	-180.3%+319.5pp	-499.8%
Current Ratio	3.50+2.8	0.72-1.4	2.12-1.2	3.35+0.2	3.14+3.0	0.16
Debt-to-Equity	0.40+3.9	-3.53-4.4	0.89+0.5	0.43-0.0	0.47+1.7	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-37.4%	N/A	276.6%	N/A	N/A	N/A	-162.7%-95.3pp	-67.4%
Return on Assets	N/A	N/A	192.1%+615.5pp	-423.5%	N/A	N/A	-50.5%-10.4pp	-40.0%
Current Ratio	4.14+0.6	3.50+0.2	3.27+3.0	0.23-0.5	0.73+0.0	0.72-0.7	1.45-1.0	2.47
Debt-to-Equity	N/A	0.40-0.0	0.44+1.7	-1.28	N/A	-3.53-5.8	2.22+1.5	0.68
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Protagenic Therapeutics Inc PTIX

$1.4M

Lipella Pharmaceuticals Inc LIPO

$11.8M

Salarius Pharmaceuticals Inc SLRX

$4.9M

Scinai Immunotherapeutics Ltd. SCNI

$1.9M

Virax Biolabs Group Ltd VRAX

$2.4M

Frequently Asked Questions

Is Gt Biopharma Inc profitable?

No, Gt Biopharma Inc (GTBP) reported a net income of -$28.4M in fiscal year 2025.

What is Gt Biopharma Inc's return on equity (ROE)?

Gt Biopharma Inc (GTBP) has a return on equity of -490.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Gt Biopharma Inc's operating cash flow?

Gt Biopharma Inc (GTBP) generated -$12.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Gt Biopharma Inc's total assets?

Gt Biopharma Inc (GTBP) had $8.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Gt Biopharma Inc spend on research and development?

Gt Biopharma Inc (GTBP) invested $3.5M in research and development during fiscal year 2025.

How many shares does Gt Biopharma Inc have outstanding?

Gt Biopharma Inc (GTBP) had 26M shares outstanding as of fiscal year 2025.

What is Gt Biopharma Inc's current ratio?

Gt Biopharma Inc (GTBP) had a current ratio of 3.50 as of fiscal year 2025, which is generally considered healthy.

What is Gt Biopharma Inc's debt-to-equity ratio?

Gt Biopharma Inc (GTBP) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Gt Biopharma Inc's return on assets (ROA)?

Gt Biopharma Inc (GTBP) had a return on assets of -349.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Gt Biopharma Inc's cash runway?

Based on fiscal year 2025 data, Gt Biopharma Inc (GTBP) had $6.8M in cash against an annual operating cash burn of $12.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Gt Biopharma Inc's Piotroski F-Score?

Gt Biopharma Inc (GTBP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Gt Biopharma Inc's earnings high quality?

Gt Biopharma Inc (GTBP) has an earnings quality ratio of 0.46x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Gt Biopharma Inc cover its interest payments?

Gt Biopharma Inc (GTBP) has an interest coverage ratio of -97.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Gt Biopharma Inc?

Gt Biopharma Inc (GTBP) scores 27 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.